Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies
Open accessThe DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index.
Abstract
Alzheimer'sdisease and Parkinson'sdisease are the most common neurodegenerative diseases. They are characterized by the degeneration of selected populations of nerve cells that develop filamentous inclusions before degeneration. The neuronal inclusions of Alzheimer'sdisease are made of the microtubule–associated protein tau, in a hyperphosphorylated state. Recent work has shown that the filamentous inclusions of Parkinson'sdisease are made of the protein α–synuclein and that rare, familial forms of Parkinson'sdisease are caused by missense mutations in the α–synuclein gene. Besides Parkinson'sdisease, the filamentous inclusions of two additional neurodegenerative diseases, namely dementia with Lewy bodies and multiple system atrophy, have also been found to be made of α–synuclein. Abundant filamentous tau inclusions are not limited to Alzheimer'sdisease. They are the defining neuropathological characteristic of frontotemporal dementias such as Pick'sdisease, and of progressive supranuclear palsy and corticobasal degeneration. The recent discovery of mutations in the tau gene in familial forms of frontotemporal dementia has provided a direct link between tau dysfunction and dementing disease. The new work has established that tauopathies and α–synucleinopathies account for most late–onset neurodegenerative diseases in man. The formation of intracellular filamentous inclusions might be the gain of toxic function that leads to the demise of affected brain cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382 · cited 6×
“Lewy bodies and Lewy neurites from dementia with Lewy bodies are strongly immunoreactive for a-synuclein, exactly as in the pathological features of Parkinson's disease (table 1, ¢gure 10) (Spillantini et al. 1997a).”
BackgroundInfluentialSelf-citationMutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · cited 1×
“Two separate missense mutations have been discovered in the a-synuclein gene in kindreds with early-onset familial Parkinson's disease (¢gure 8) (Polymeropoulos et al. 1997; KrÏger et al. 1998).”
BackgroundGlenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404 · cited 6×
“Although some staining for hyperphosphorylated tau has been described in nerve cell processes around Ab deposits in transgenic mice expressing mutated APP, no somatodendritic staining of hyperphosphorylated tau was observed in these mice.”
BackgroundInfluentialGoate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619 · cited 5×
“Although some staining for hyperphosphorylated tau has been described in nerve cell processes around Ab deposits in transgenic mice expressing mutated APP, no somatodendritic staining of hyperphosphorylated tau was observed in these mice.”
BackgroundInfluentialAmyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · cited 7×
“Although some staining for hyperphosphorylated tau has been described in nerve cell processes around Ab deposits in transgenic mice expressing mutated APP, no somatodendritic staining of hyperphosphorylated tau was observed in these mice.”
BackgroundInfluentialCorrelative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · cited 5×
“Although some staining for hyperphosphorylated tau has been described in nerve cell processes around Ab deposits in transgenic mice expressing mutated APP, no somatodendritic staining of hyperphosphorylated tau was observed in these mice.”
BackgroundInfluentialAlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Cited by
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Intrinsically Disordered Proteins in Human Diseases: Introducing the D2Concept
Uversky, V. N., Oldfield, C. J., & Dunker, A. K. (2008) · Annual Review of Biophysics · doi:10.1146/annurev.biophys.37.032807.125924 · Cited by 1,410
Amyloid fibrillogenesis: themes and variations
Rochet, J.-C., & Lansbury, P. T. (2000) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(99)00049-4 · Cited by 1,095
Role of tau protein in both physiological and pathological conditions
AVILA, J., LUCAS, J. J., PÉREZ, M., & HERNÁNDEZ, F. (2004) · Physiological Reviews · doi:10.1152/physrev.00024.2003 · Cited by 1,005
“In AD, there is an inverse correlation between the number of extracellular tangles and the number of surviving neurons, suggesting that neurons developing neurofibrillary lesions could degenerate (82).”
BackgroundBendor, J. T., Logan, T. P., & Edwards, R. H. (2013) · Neuron · doi:10.1016/j.neuron.2013.09.004 · Cited by 825
Lee, M. K., Stirling, W., Xu, Y., Xu, X., Qui, D., Mandir, A. S., Dawson, T. M., Copeland, N. G., Jenkins, N. A., & Price, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132197599 · Cited by 824
Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases
Guo, J. L., & Lee, V. M. Y. (2014) · Nature Medicine · doi:10.1038/nm.3457 · Cited by 641
Spira, P. J., Sharpe, D. M., Halliday, G., Cavanagh, J., & Nicholson, G. A. (2001) · Annals of Neurology · doi:10.1002/ana.67 · Cited by 627
Neuropathology, biochemistry, and biophysics of α‐synuclein aggregation
Uversky, V. N. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04764.x · Cited by 567
Uversky, V. N. (2003) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2003.10506918 · Cited by 500
Synucleinopathies: Clinical and Pathological Implications
Galvin, J. E., Lee, V. M.-Y., & Trojanowski, J. Q. (2001) · Archives of Neurology · doi:10.1001/archneur.58.2.186 · Cited by 466
The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases
Lackie, R. E., Maciejewski, A., Ostapchenko, V. G., Marques-Lopes, J., Choy, W.-Y., Duennwald, M. L., Prado, V. F., & Prado, M. A. M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00254 · Cited by 374
Cohlberg, J. A., Li, J., Uversky, V. N., & Fink, A. L. (2002) · Biochemistry · doi:10.1021/bi011711s · Cited by 340
Hebron, M. L., Lonskaya, I., & Moussa, C. E. H. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt192 · Cited by 325
Biophysics of Parkinsons Disease: Structure and Aggregation of α- Synuclein
Uversky, V., & Eliezer, D. (2009) · Current Protein & Peptide Science · doi:10.2174/138920309789351921 · Cited by 322
Distinct β-sheet structure in protein aggregates determined by ATR-FTIR spectroscopy
Shivu, B., Seshadri, S., Li, J., Oberg, K. A., Uversky, V. N., & Fink, A. L. (2013) · Biochemistry · doi:10.1021/bi400625v · Cited by 289
Tau phosphorylation and aggregation in Alzheimer's disease pathology
Avila, J. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.02.067 · Cited by 282
Unfoldomics of human diseases: linking protein intrinsic disorder with diseases
Uversky, V. N., Oldfield, C. J., Midic, U., Xie, H., Xue, B., Vucetic, S., Iakoucheva, L. M., Obradovic, Z., & Dunker, A. K. (2009) · BMC Genomics · doi:10.1186/1471-2164-10-s1-s7 · Cited by 281
Gai, W. P., Yuan, H. X., Li, X. Q., Power, J. T. H., Blumbergs, P. C., & Jensen, P. H. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7527 · Cited by 272
Extracellular tau is toxic to neuronal cells
Gómez-Ramos, A., Díaz-Hernández, M., Cuadros, R., Hernández, F., & Avila, J. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.07.078 · Cited by 241
“degenerate, might release the NFT into the extracellular environment [12].”
BackgroundInflammation in the early stages of neurodegenerative pathology
Khandelwal, P. J., Herman, A. M., & Moussa, C. E.-H. (2011) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2011.07.002 · Cited by 212
Noradrenergic Modulation of Cognition in Health and Disease
Borodovitsyna, O., Flamini, M., & Chandler, D. (2017) · Neural Plasticity · doi:10.1155/2017/6031478 · Cited by 205
“Mutations in the α-synuclein gene could cause it to polymerize into filaments, which, with time, leads to nerve degeneration [117].”
BackgroundTau Oligomers Impair Artificial Membrane Integrity and Cellular Viability
Flach, K., Hilbrich, I., Schiffmann, A., Gärtner, U., Krüger, M., Leonhardt, M., Waschipky, H., Wick, L., Arendt, T., & Holzer, M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.396176 · Cited by 188
Amyloidogenesis of Natively Unfolded Proteins
Uversky, V. (2008) · Current Alzheimer Research · doi:10.2174/156720508784533312 · Cited by 188
Abnormal Tau-Containing Filaments in Neurodegenerative Diseases
Crowther, R. A., & Goedert, M. (2000) · Journal of Structural Biology · doi:10.1006/jsbi.2000.4270 · Cited by 185
Self-citationβ-Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease
Buttini, M., Masliah, E., Barbour, R., Grajeda, H., Motter, R., Johnson-Wood, K., Khan, K., Seubert, P., Freedman, S., Schenk, D., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1697-05.2005 · Cited by 176
“…A and plaques emerge as the main pathogenic factors in various lines of hAPP mice, other processes not modeled in these mice, such as tau pathology (Goedert, 1999; Johnson and Stoothoff, 2004), vascular pathology (Jellinger, 2005), or aberrant inflammation (Wyss-Coray and Mucke, 2002), may…”
BackgroundGSK3β and tau protein in Alzheimer's disease and epilepsy
Toral-Rios, D., Pichardo-Rojas, P. S., Alonso-Vanegas, M., & Campos-Peña, V. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00019 · Cited by 158
“Under pathological conditions, it self-assembles into insoluble structures, known as paired helical filaments (PHFs; Goedert, 1999).”
BackgroundHERNANDEZ, F. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.04.002 · Cited by 41
Wang, Z.-Y., Han, Z.-M., Liu, Q.-F., Tang, W., Ye, K., & Yao, Y.-Y. (2015) · International Psychogeriatrics · doi:10.1017/s1041610215000447 · Cited by 39
The muscle protein dysferlin accumulates in the Alzheimer brain
Galvin, J. E., Palamand, D., Strider, J., Milone, M., & Pestronk, A. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0147-8 · Cited by 36
“Whether due to point mutations or post-translational modiWcation, normally soluble proteins are altered and form insoluble Wbrillar aggregates [18].”
Background
Metadata
- Authors
- Goedert, M.
- Venue
- Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences
- Publisher
- The Royal Society
- Published
- 1999-06-29
- Volume
- 354
- Issue
- 1386
- Pages
- 1101-1118
- ISSN
- 0962-8436 (ISSN-L)
- 1471-2970
- OpenAlex
- W2096180119
- Cited by
- 172
- References
- 145
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.